Serum paraoxonase and arylesterase can be useful markers to predict neoadjuvant chemotherapy requirement in patients with breast cancer

OKUTURLAR Y., Gunaldi M., Kocoglu H., Hursitoglu M., GEDİKBAŞI A., Acarer D., ...Daha Fazla

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, cilt.14, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 14
  • Basım Tarihi: 2018
  • Doi Numarası: 10.4103/0973-1482.235355
  • Dergi Adı: JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: Arylesterase, breast cancer, cancer risk, cut-off value, neoadjuvant, paraoxonase, screening, BODY-MASS INDEX, COLORECTAL-CANCER, OXIDATIVE STRESS, CARCINOGENESIS, INFLAMMATION, POLYMORPHISM, RADICALS, PON1, RISK
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Aim: The aims of this study are to evaluate the serum levels of paraoxonase (PON) and arylesterase (ARE) in breast cancer (BC) patients; to determine their relationship with chemotherapy requirements in BC; and to find a cut-off value to assess subjects with a higher risk of BC.